Chemotherapy for ER Positive Breast Cancer: 143 Real Stories

143 stories match breast cancer, ER positive and chemotherapy. 134 of them mention surgery.

Cancer Stories

Ann, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Stage IV HR-Positive Invasive Lobular Carcinoma: Ann's Patient Story

Patient Info: Ann, Female | Stage IV

Biomarkers: ER-positive; HER2-negative

Metastatic Site: peritoneum; intestines/bowel

Ann was living with metastatic invasive lobular breast cancer involving the peritoneum and bowel. After 9 months of recurrence treatment, she underwent successful ileostomy reversal and regained greater freedom to travel.

breastcancer.org
OutcomeLiving With Cancer
Jenna, who was diagnosed with Breast CancerBreast Cancer

HR-Positive Breast Cancer: Jenna's Patient Story

Patient Info: Jenna, Female, Under 40

Biomarkers: ER-positive

Jenna completed 10 rounds of chemotherapy and double mastectomy for ER-positive breast cancer with lymph-node involvement. She was recovering, planning reconstruction, and preparing for long-term tamoxifen.

breastcancer.org
OutcomeCare Ongoing
Tanya, who was diagnosed with Stage II Invasive Lobular CarcinomaBreast Cancer

Stage II HR-Positive Invasive Lobular Carcinoma: Tanya's Patient Story

Patient Info: Tanya, Female, 40s | Stage II

Biomarkers: Genetic testing negative; Oncotype DX score 27; MammaPrint low risk; ER-positive

Tanya had Stage II ER-positive breast cancer with a large lobular tumor found on MRI, underwent bilateral mastectomy with immediate reconstruction, completed 4 rounds of chemotherapy, and started tamoxifen.

Lobular Breast Cancer Alliance
OutcomeCare Ongoing
Robbie, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HR-Positive Breast Cancer: Robbie's Patient Story

Patient Info: Robbie, Female | Stage IV

Biomarkers: Estrogen receptor-positive / ER-positive

Metastatic Site: Bone; liver

Living with metastatic breast cancer involving bone and liver after earlier DCIS and Stage II ER-positive breast cancer; ongoing treatment at Mass General focused on stabilization and long-term disease management.

Massachusetts General Hospital
OutcomeLiving With Cancer
Eutha, who was diagnosed with Stage II Invasive Lobular CarcinomaBreast Cancer

Stage II HR-Positive Invasive Lobular Carcinoma: Eutha's Survivor Story

Patient Info: Eutha, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

Eutha completed clinical-trial immunotherapy, right mastectomy with lymph-node removal, chemotherapy, radiation and reconstruction for Stage II ER-positive, PR-positive, HER2-positive breast cancer, and returned to work and community life; no explicit NED/cancer-free status was provided.

Memorial Sloan Kettering
OutcomeSurvivorship / Surveillance
Alison, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HR-Positive Breast Cancer: Alison's Survivor Story

Patient Info: Alison, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Cervical/neck lymph nodes

Alison reported complete remission since August 2017 while continuing intermittent maintenance chemotherapy, most recently 1 month of treatment followed by 2 months off.

The Patient Story
OutcomeLiving With Cancer / Remission
Stefanie, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Stage III HR-Positive Invasive Ductal Carcinoma: Stefanie's Survivor Story

Patient Info: Stefanie, Female | Stage III

Biomarkers: ER-positive, PR-positive and HER2-positive

Stefanie completed chemotherapy, breast-conserving surgery, prolonged Herceptin and 30 radiation treatments, then moved into survivorship while still adjusting to the lasting effects of treatment.

The Patient Story
OutcomeTreatment Completed / Survivorship
Shari, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage IV HR-Positive Invasive Ductal Carcinoma: Shari's Patient Story

Patient Info: Shari S., Female | Stage IV

Biomarkers: ER-positive, PR-positive and HER2-positive; no inherited cancer mutation was identified

Metastatic Site: Brain; other initial metastatic sites were not named

Systemic imaging after chemotherapy showed no active disease, but brain metastases later required stereotactic radiation. Shari remained stage 4, continued Herceptin every 3 weeks and underwent brain MRI every 3–4 months.

The Patient Story
OutcomeLiving With Cancer / Ongoing Therapy
A patient, who was diagnosed with Breast CancerBreast Cancer

Breast cancer treatment in a woman with mirror-image organ anatomy

Patient Info: Anonymized, Female

Biomarkers: ER-positive; HER2-negative

A woman in her early 60s with mirror-image organ anatomy received chemotherapy and mastectomy for left breast cancer after a specially planned venous port placement.

PubMed Central
OutcomeNot reported
Rach, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II HR-Positive Breast Cancer: Rach's Patient Story

Patient Info: Rach D., Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of June 2026, Rach described Stage II triple-positive breast cancer treated with fertility preservation, 6 rounds of neoadjuvant TCHP including Herceptin, Zoladex ovarian suppression, and double mastectomy with reconstruction.

The Patient Story
OutcomeCare Ongoing
Tina, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage III HR-Positive Invasive Lobular Carcinoma: Tina's Patient Story

Patient Info: Tina, Female, Under 40 | Stage III

Biomarkers: ER-positive

As of June 2026, Tina was in survivorship after double mastectomy, AC-T chemotherapy, radiation, and ongoing hormone therapy with daily tamoxifen and Zoladex every 3 months.

The Patient Story
OutcomeCare Ongoing
Genoa, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III HER2-Positive Breast Cancer: Genoa's Survivor Story

Patient Info: Genoa M., Female | Stage III

Biomarkers: HER2-positive; ER-positive

As of June 2026, Genoa had completed treatment for Stage III HER2-positive, ER-positive breast cancer with neoadjuvant Taxotere/carboplatin/trastuzumab, lumpectomy, and radiation, and was focused on survivorship and rebuilding life after treatment.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Amelia, who was diagnosed with Stage I Invasive Ductal CarcinomaBreast Cancer

Stage I HR-Positive Invasive Ductal Carcinoma: Amelia's Patient Story

Patient Info: Amelia, Female, 40s | Stage I

Biomarkers: ER-positive; PR-positive; HER2-negative; BRCA negative; Oncotype DX score 22

As of June 2026, Amelia had no evidence of disease after lumpectomy, bilateral mastectomy, TC chemotherapy, and reconstruction, and she remained on tamoxifen.

The Patient Story
OutcomeCare Ongoing
Cat, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Cat's Survivor Story

Patient Info: Cat, Female | Stage II

Biomarkers: ER-positive; Oncotype recurrence risk discussed

As of June 2026, Cat described being cancer-free after bilateral mastectomy, 4 months of chemotherapy, reconstruction, and a period on tamoxifen for ER-positive Stage IIB breast cancer.

The Patient Story
OutcomeCancer-Free / NED
Bethany, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II HR-Positive Breast Cancer: Bethany's Patient Story

Patient Info: Bethany W., Female, Under 40 | Stage II

Biomarkers: ER-positive; hormone-positive

As of June 2026, Bethany described care for late Stage II/early Stage III ER-positive breast cancer, beginning with AC chemotherapy and Taxol after scans showed no distant spread, with surgery, radiation, and hormone therapy planned as next phases.

The Patient Story
OutcomeCare Ongoing
Doreen, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Doreen's Patient Story

Patient Info: Doreen, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of June 2026, Doreen had completed TCHP chemotherapy with a complete response before surgery and had undergone lumpectomy and radiation for Stage IIA triple-positive breast cancer.

The Patient Story
OutcomeResponding Well
Callie, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Callie's Survivor Story

Patient Info: Callie, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of June 2026, Callie described survivorship after mastectomy, ACT chemotherapy, reconstruction, and hysterectomy for Stage IIB ER-positive IDC, with all cancer-directed treatment completed by the end of 2019.

The Patient Story
OutcomeSurvivorship / Completed Treatment
SI
Breast Cancer

Stage I luminal A invasive ductal breast cancer with post-treatment cognitive symptoms

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: ER 100% positive; PR 95% positive; HER2 score 0 / HER2-negative; Ki-67 10%; P63 negative

As of April 2026, the case focused on survivorship after Stage I luminal A breast cancer treatment, with cognitive complaints after chemotherapy and improved MoCA and depression scores after 12 sessions of tDCS; brain metastases had been ruled out.

PubMed Central
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Metastatic invasive lobular breast cancer with stomach, ovarian, peritoneal, rectal, and jejunal spread

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Primary tumor and gastric metastasis were ER/PR positive and HER2 negative; GATA3 supported breast origin in the metastasis.

Metastatic Site: stomach; ovaries; peritoneum; rectum; jejunum

During 2025, she remained under active oncologic management for metastatic invasive lobular breast cancer with gastrointestinal, ovarian, peritoneal, rectal, and jejunal involvement.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

ER-positive/HER2-positive breast cancer with rare paranasal sinus and skull metastasis

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary and paranasal sinus metastasis were ER positive, PR negative, HER2 positive; GATA3 supported breast origin in metastasis.

Metastatic Site: left frontal sinus; ethmoid air cells; posterior…

The paranasal sinus/skull metastasis did not respond to palliative radiotherapy; her condition deteriorated and she died 2 years after her initial presentation to the treating facility.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Invasive lobular breast cancer with colonic metastases treated with colectomy and capecitabine

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Breast and colon metastatic samples were ER+ and HER2-; PR varied by sample

Metastatic Site: colon; perivisceral lymph nodes

After laparoscopic left colectomy and capecitabine for colonic metastases, follow-up showed no clinical or radiological evidence of recurrence or progression at 8 months postoperatively.

PubMed Central
OutcomeResponding Well
Janet, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Janet's Patient Story

Patient Info: Janet Ayala, Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; ATM mutation

After complete pathologic response and completion of HER2-targeted infusions, Janet remained in survivorship-focused ongoing care with estrogen suppression and additional endocrine/targeted therapy planning to reduce recurrence risk.

City of Hope
OutcomeCare Ongoing